Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00657904 · ClinicalTrials.gov registry record · Phase 3
Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,618
- Enrollment target
NCT00657904: Completed Phase 3 study, sponsored by AstraZeneca.
NCT00657904 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 3,618 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (369% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00657904, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,618 participants
- Enrollment target
Study Summary
The purpose of this trial is to study the effect - in terms of time to progression and overall survival - of 2 years of adjuvant bicalutamide 150mg monotherapy, versus placebo, in subjects with histologically or cytologically confirmed non-metastatic adenocarcinoma of the prostate gland.
Interventions
- DRUG Placebo
- DRUG Bicalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,618 participants |
| Start Date | 1995-08 |
| Est. Completion | 2008-08 |
| Phase | Phase 3 |
What the finished NCT00657904 record still lists
NCT00657904 is an interventional study that assigns participants to a tested intervention. Its 3,618 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (369% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00657904 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00657904 about?
NCT00657904 is a clinical study titled "Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer". The purpose of this trial is to study the effect - in terms of time to progression and overall survival - of 2 years of adjuvant bicalutamide 150mg monotherapy, versus placebo, in subjects with histologically or cytologically confirmed non-metastatic adenocarcinoma of the prostate gland.
What is the current status of trial NCT00657904?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,618 participants. The study started on 1995-08. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00657904?
The interventions under investigation include: Placebo (DRUG), Bicalutamide (DRUG).
Who is sponsoring clinical trial NCT00657904?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00657904's enrollment target sits among peer trials
3,618 68th of 2000 higher than 1,933 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06354920 · 3,624 participants · NA
M-Well Bonding Bundle to Improve Patient-Physician Relationships
- NCT06088498 · 3,600 participants · Phase 2
App for Reducing Cravings to Smoke
- NCT06501118 · 3,600 participants · NA
Optimizing Care in Critically Ill at UCHealth by Liberalizing the Target O2 in Mechanically-ventilated ICU Patients
- NCT06919419 · 3,600 participants · NA
HOTSPOT Study: Implement and Evaluate the PrEP (Pre-exposure Prophylaxis) Implementation Strategy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia